Neuromyelitis Optica Spectrum Disorder Attack
6
2
3
0
Key Insights
Highlights
Treatment Research
8 treatments under study, led by Complement Protein C5 Inhibitor
Research Leaders
5 sponsors active, led by Tianjin Medical University General Hospital
Related Conditions
Often studied with 6 related conditions
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 75/100
16.7%
1 terminated out of 6 trials
0.0%
-86.6% vs benchmark
17%
1 trials in Phase 3/4
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Clinical Trials (6)
Safety and Efficacy Study of Sivelestat in Neuromyelitis Optica Spectrum Disorder
Eculizumab For the Acute Attack of Neuromyelitis Optica Spectrum Disorder
Therapy in the Acute Phase of NMOSD: A Multicenter Prospective Real-World Study
Eculizumab For Acute Attack of Neuromyelitis Optica Spectrum Disorder
Diagnosis of ON With or Without MS or NMOSD
Acute Optic Neuritis Network: an International Study That Invesitages Subjects With a First-ever Episode of Acute Inflammation of the Optic Nerve
Research Network
Common Treatments
- Complement Protein C5 Inhibitor2
- Ivmp2
- Ivigivmp1
- Eculizumabivmp1
- Noninterventional Study1
Active Sponsors
- Tianjin Medical University General Hospital2
- Chinese PLA General Hospital1
- Kyushu University1
- Jagannadha R Avasarala1
- Experimental and Clinical Research Center, a cooperation between the Max Delbrück Center for Molecul1
Top Investigators
Rabin Medical Center, Tel Aviv
Charite University, Berlin, Germany
University of Kentucky
Related Conditions
- Optic Neuritis2
- Multiple Sclerosis2
- Demyelinating Diseases1
- Neuromyelitis Optica Spectrum Disorder Progression1
- Myelin Oligodendrocyte Glycoprotein Antibodyassociated Disease1